FDA Approved Generic Everolimus Tablets

The drug approval covers three dosage strengths of the treatment that acts as a generic version of Afinitor Disperz.

Updated on Sept. 23, 2026 in Cancer

Isometric editorial illustration of three white circular pharmaceutical tablets on a steel tray, representing the generic drug approval process. — The FDA has approved ANI Pharmaceuticals to market generic versions of Everolimus, a move expected to lower costs for patients requiring this treatment. AI Illustration. Upload story photo >

Live Poll

Does the approval of generic drugs play a vital role in reducing your healthcare costs?

The FDA has granted approval for ANI Pharmaceuticals to market its generic version of the drug Everolimus Tablets for Oral Suspension. The medication is now authorized for production in 2mg, 3mg, and 5mg dosage strengths.

Why it matters

Generic drug approvals are intended to increase patient access to lower-cost versions of established medications. This authorization brings a new competitor to the market for a drug that saw significant annual sales in the United States.

The FDA approved the drug in 2mg, 3mg, and 5mg strengths. The brand-name equivalent, Afinitor Disperz, recorded annual U.S. sales of approximately $123 million as of July 2026.

The players

FDA

The U.S. Food and Drug Administration is the federal agency responsible for protecting public health by ensuring the safety and efficacy of medical products.

ANI Pharmaceuticals

This Princeton-based company is a specialty pharmaceutical business that develops and manufactures generic and branded prescription drugs.

The details

ANI Pharmaceuticals, based in Princeton, N.J., secured this approval after submitting an Abbreviated New Drug Application to the federal agency. The firm has indicated a broader strategy to expand its portfolio with a goal of launching at least 15 new generic products this year.

The annual sales figure was calculated based on data from July 2026.
The FDA officially announced the approval on September 23, 2026.

Diabetes
Sept. 18
FDA Approved Generic Lanreotide Injection
Cancer
Sept. 21
FDA Conditionally Accepted Name for Lirafugratinib
Cancer
Sept. 18
FDA Approved New Breast Cancer Combination Therapy

The Big Picture

This approval follows the established regulatory pattern set by the Hatch-Waxman Act for bringing generic pharmaceuticals to market. The move reflects the ongoing industry push to reduce costs by providing alternatives to brand-name treatments.

Patients may soon have access to a more affordable generic option for their existing medication regimen. Those prescribed Everolimus should consult their healthcare provider to determine if the new generic version is a suitable substitute.

The takeaway

Generic drug options provide essential cost savings for patients managing long-term health conditions. Patients should always verify with their pharmacist or doctor whether a generic switch will impact their specific treatment plan.